The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Consensus Recommendations Guide Sjögren’s Syndrome Management

New Consensus Recommendations Guide Sjögren’s Syndrome Management

November 25, 2019 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—New consensus-based recommendations from the European League Against Rheumatism (EULAR) address the management of Sjögren’s syndrome with topical and systemic therapies.

You Might Also Like
  • Recommendations for Sjögren’s Syndrome: How to Address Biologics & Musculoskeletal Pain
  • New Osteoarthritis Recommendations and Classification Criteria for Sjögren’s Syndrome and Polymyalgia Rheumatica
  • ACR, EULAR Approve New Classification Criteria for Primary Sjögren’s Syndrome

Sjögren’s syndrome presents with a broad spectrum of clinical manifestations and autoantibodies, including antinuclear antibodies (the most frequently detected), anti-Ro/SS-A (the most specific) and cryoglobulins and hypocomplementemia (the main prognostic markers).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For decades, the management of Sjögren’s syndrome has been based on symptomatic treatment of sicca symptomatology and broad-spectrum immunosuppression for systemic disease, yet there is little information on the relative efficacy and safety of the available therapeutic options.

Dr. Manuel Ramos-Casals from Hospital Clinic of Barcelona, Spain, and colleagues on the EULAR-Sjögren Syndrome Task Force reviewed the existing evidence and used a Delphi procedure to develop consensus recommendations for the management of Sjögren’s syndrome.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Three general principles underlie a dozen specific recommendations:

  • Patients with Sjögren’s syndrome should be managed at, or in close collaboration with, centers of expertise following a multidisciplinary approach;
  • The first therapeutic approach for dryness should be symptomatic relief using topical therapies; and
  • Systemic therapies may be considered for treatment of active systemic disease.

After evaluation of salivary gland function, treatment for oral dryness should include nonpharmacological stimulation for mild dysfunction, pharmacological stimulation for moderate dysfunction and saliva substitutes for severe dysfunction, the authors advise.

Ocular dryness should be treated first with artificial tears and ocular gels/ointments, followed by topical immunosuppressive-containing drops and autologous serum eyedrops for refractory or severe ocular dryness.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Musculoskeletal pain can be managed with analgesics or other pain-modifying agents while balancing their potential benefits and side effects.

Treatment of systemic disease should be tailored to organ-specific severity using the EULAR Sjögren’s syndrome disease activity index (ESSDAI) definitions, according to the report, online Oct. 31 in Annals of the Rheumatic Diseases.1

As a general rule, the systemic organ-specific therapeutic approach should consist of the sequential or combined use of glucocorticoids, immunosuppressive agents and biologics.

“The task force is convinced that adhering to these recommendations, including shared decision making, assessing disease activity regularly with the ESSDAI instrument, and applying the sequence of drugs as proposed, will improve overall outcomes in a clear majority of patients with Sjögren’s syndrome,” the authors conclude.

“New research information on treatment strategies, predictive markers, and other aspects will soon become available and will probably require an update of the recommendations in coming years,” they add. “Until then, we hope that the current recommendations will be broadly applied in clinical practice and/or serve as a template for national societies to develop local recommendations.”

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: EULAR, guideline, recommendations, Sjögren's syndrome

You Might Also Like:
  • Recommendations for Sjögren’s Syndrome: How to Address Biologics & Musculoskeletal Pain
  • New Osteoarthritis Recommendations and Classification Criteria for Sjögren’s Syndrome and Polymyalgia Rheumatica
  • ACR, EULAR Approve New Classification Criteria for Primary Sjögren’s Syndrome
  • New Recommendations Guide Imaging in Large-Vessel Vasculitis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.